Publications by authors named "M Yiamunaa"
Aims: We aim to determine the association of seven major candidate protein biomarkers and diabetic kidney disease (DKD) progression among Asians with young-onset type 2 diabetes mellitus (T2DM).
Methods: 824 T2DM patients (onset ≤ 40 years old) were classified as DKD progressors based on yearly estimated glomerular filtration rate (eGFR) decline of >3 ml/min/1.73 m or >40 % from baseline.
Circulating ceramide levels are dysregulated in kidney disease. However, their associations with rapid decline in kidney function (RDKF) and end-stage kidney disease (ESKD) in patients with type 2 diabetes (T2D) are unknown. In this prospective study of 1746 T2D participants, we examined the association of plasma ceramide Cer16:0, Cer18:0, Cer24:0, and Cer24:1 with RDKF, defined as an estimated glomerular filtration rate (eGFR) decline of 5 ml/min/1.
View Article and Find Full Text PDFPlasma Proteomics of Diabetic Kidney Disease Among Asians With Younger-Onset Type 2 Diabetes.
J Clin Endocrinol Metab
January 2025
Article Synopsis
- Patients with younger onset type 2 diabetes (YT2D) face a higher risk for kidney failure, yet the progression mechanism of diabetic kidney disease (DKD) in this group is not well understood.
- A study involving 144 DKD progressors and 292 non-progressors aimed to find new biomarkers and causal proteins linked to DKD progression in YT2D, utilizing proteomic analysis and logistic regression methods.
- Results identified 42 plasma proteins related to DKD progression, with angiogenin emerging as a significant factor, indicating its potential role in the disease's advancement.
Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes.
Cardiovasc Diabetol
February 2024
Background: Angiogenin, an enzyme belonging to the ribonucleases A superfamily, plays an important role in vascular biology. Here, we sought to study the association of plasma angiogenin and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes (T2D).
Methods: This prospective study included 1083 T2D individuals recruited from a secondary hospital and a primary care facility.
Article Synopsis
- The study investigates how metabolites in the tryptophan-kynurenine pathway affect the risk of developing end-stage kidney disease (ESKD) in type 2 diabetes patients.
- In a large sample size across multiple cohorts, higher levels of tryptophan and certain metabolites (kynurenic and xanthurenic acids) were linked to a lower risk of ESKD, while a higher kynurenine-to-tryptophan ratio indicated increased risk.
- The findings suggest that managing tryptophan metabolism may help slow kidney function decline in diabetic patients.